These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 19362307)

  • 21. Polycystic ovarian syndrome in the adolescent-the focus is new and exciting.
    Sanfilippo JS
    J Pediatr Adolesc Gynecol; 2008 Jun; 21(3):113-4. PubMed ID: 18549961
    [No Abstract]   [Full Text] [Related]  

  • 22. Gut hormones, obesity, polycystic ovarian syndrome, malignancy, and lipodystrophy syndromes.
    Bloomgarden ZT
    Diabetes Care; 2007 Jul; 30(7):1934-9. PubMed ID: 17596508
    [No Abstract]   [Full Text] [Related]  

  • 23. Changes in physiology with increasing fat mass.
    Schuster DP
    Semin Pediatr Surg; 2009 Aug; 18(3):126-35. PubMed ID: 19573754
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Dehydroepiandrosterone sulfate].
    Suzuki M
    Nihon Rinsho; 1998 Jan; 56 Suppl 3():201-5. PubMed ID: 9513415
    [No Abstract]   [Full Text] [Related]  

  • 25. Insulin resistance in pediatric disease.
    Bremer AA
    Pediatr Ann; 2012 Feb; 41(2):e1-7. PubMed ID: 22299621
    [No Abstract]   [Full Text] [Related]  

  • 26. Drug treatments for polycystic ovary syndrome.
    Radosh L
    Am Fam Physician; 2009 Apr; 79(8):671-6. PubMed ID: 19405411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dehydroepiandrosterone sulfate has not been substantiated as an anabolic hormone.
    Dhatariya K
    Arch Intern Med; 2008 Jul; 168(13):1470; author reply 1470. PubMed ID: 18625932
    [No Abstract]   [Full Text] [Related]  

  • 28. [Treatment of the polycystic ovarian syndrome with an ester of prednisolone].
    Vázquez E; Vázquez P; Mendoza M
    Ginecol Obstet Mex; 1971 Sep; 30(179):331-8. PubMed ID: 5116629
    [No Abstract]   [Full Text] [Related]  

  • 29. [Combined analyses of paraoxonase-1 and IGF-2 polymorphism in polycystic ovary syndrome].
    Knebel B; Janssen OE; Hahn S; Nitzgen U; Jacob S; Haas J; Mack S; Müller-Wieland D; Kotzka J
    Dtsch Med Wochenschr; 2009 May; 134(20):1040-6. PubMed ID: 19421925
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Polycystic ovary syndrome. Diet helps control hormone chaos].
    Klein F
    MMW Fortschr Med; 2009 Sep; 151(37):16. PubMed ID: 19827418
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparison of aerobic exercise capacity and muscle strength in overweight women with and without polycystic ovary syndrome.
    Thomson RL; Buckley JD; Moran LJ; Noakes M; Clifton PM; Norman RJ; Brinkworth GD
    BJOG; 2009 Aug; 116(9):1242-50. PubMed ID: 19438498
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effect of electroacupuncture combined with auricular point tapping and pressing on serum insulin and testosterone in the patients of obese women with polycystic ovary syndrome].
    Xu J; Qu HQ; Fang HL
    Zhongguo Zhen Jiu; 2009 Jun; 29(6):441-3. PubMed ID: 19563188
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Criteria for the polycystic ovary syndrome.
    Acién P
    Fertil Steril; 2009 Jul; 92(1):e14; author reply e15. PubMed ID: 19481742
    [No Abstract]   [Full Text] [Related]  

  • 34. Adrenal plasma steroid relations in glucocorticoid-naïve premenopausal rheumatoid arthritis patients during insulin-induced hypoglycemia test compared to matched normal control females.
    Imrich R; Vigas M; Rovensky J; Aldag JC; Masi AT
    Endocr Regul; 2009 Apr; 43(2):65-73. PubMed ID: 19856711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin.
    Svendsen PF; Nilas L; Madsbad S; Holst JJ
    Metabolism; 2009 May; 58(5):586-93. PubMed ID: 19375579
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adrenal morphologic considerations in polycystic ovary syndrome.
    Gonzalez F; Speroff L
    Obstet Gynecol Surv; 1990 Aug; 45(8):491-508. PubMed ID: 2198502
    [No Abstract]   [Full Text] [Related]  

  • 37. What Is the Male Polycystic Ovary Syndrome Phenotype?
    Welt CK
    J Clin Endocrinol Metab; 2022 Apr; 107(5):e2188-e2189. PubMed ID: 34905059
    [No Abstract]   [Full Text] [Related]  

  • 38. Targeting insulin sensitivity in the treatment of polycystic ovary syndrome.
    Pasquali R; Gambineri A
    Expert Opin Ther Targets; 2009 Oct; 13(10):1205-26. PubMed ID: 19650762
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of pharmaceutical intervention on lipid profile in polycystic ovary syndrome.
    Diamanti-Kandarakis E; Kandaraki E; Christakou C; Panidis D
    Obes Rev; 2009 Jul; 10(4):431-41. PubMed ID: 19413702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of the endogenous opioid system in polycystic ovary syndrome.
    Eyvazzadeh AD; Pennington KP; Pop-Busui R; Sowers M; Zubieta JK; Smith YR
    Fertil Steril; 2009 Jul; 92(1):1-12. PubMed ID: 19560572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.